Related Experiment Video
Updated: Jan 11, 2026
03:52
The Creation of a Rat Model for Osteosarcopenia via Ovariectomy
Published on: February 21, 2025
1.1K
Sarcopenia in Chronic Obstructive Pulmonary Disease
Sukriye Gundogdu1, Halil Ibrahim Yakar1, Handan Inonu Koseoglu1
1Department of Pulmonary Disease, Faculty of Medicine, Tokat Gaziosmanpasa University, Tokat, Turkiye.
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
|November 17, 2025
Summary
Sarcopenia, a loss of muscle mass, is significantly more common in patients with chronic obstructive pulmonary disease (COPD) than in healthy individuals. This condition is most prevalent in severe COPD (Group E) and warrants consideration in patient management.
Area of Science:
- Pulmonary Medicine
- Geriatrics
- Muscle Physiology
Background:
- Chronic obstructive pulmonary disease (COPD) is a progressive lung condition associated with systemic effects.
- Sarcopenia, characterized by loss of muscle mass and strength, is an increasingly recognized comorbidity in COPD.
- Inflammation and reduced muscle mass are key factors in COPD pathophysiology.
Purpose of the Study:
- To determine the prevalence of sarcopenia in patients with COPD compared to a control group.
- To compare functional parameters including the 6-minute walk test (6MWT), handgrip strength (HGS), pulmonary function tests (PFTs), and bioimpedance analysis (BIA) across different COPD severity groups (GOLD A, B, and E).
Main Methods:
- A cohort study was conducted involving 43 COPD patients and 40 healthy volunteers.
- COPD diagnosis and staging followed GOLD 2022 criteria.
- Sarcopenia incidence, HGS, 6MWT, PFTs, and BIA parameters were assessed and compared between groups.
Main Results:
- The incidence of sarcopenia was significantly higher in the COPD group (39.5%) compared to the control group.
- Sarcopenia prevalence was highest in GOLD Group E COPD patients (70%).
- COPD patients exhibited lower handgrip strength (HGS) compared to controls (p=0.019 for uncorrected HGS, p=0.005 for age and gender-corrected HGS).
Conclusions:
- Sarcopenia is a prevalent condition in COPD patients, particularly in severe disease (Group E).
- Reduced muscle strength (HGS) is evident in COPD patients.
- Integrating sarcopenia screening and therapeutic interventions, such as nutritional support and pulmonary rehabilitation, is recommended for COPD management.
Related Concept Videos
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
4.2K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
4.2K
01:22Chronic Obstructive Pulmonary Disease
2.2K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.2K
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
3.5K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
3.5K
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
3.5K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.5K
01:20COPD: Pathogenesis and Clinical Features
1.7K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.7K
01:29Chronic Obstructive Pulmonary Disease-V: Management
3.1K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.1K